| Market Cap | 9.80B | P/E | 37.67 | EPS this Y | - | Ern Qtrly Grth | -3.10% |
| Income | 227M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 1.00% |
| Sales | 1.33B | PEG | - | EPS past 5Y | - | 200D Avg Chg | 4.00% |
| Dividend | 5.00% | Price/Book | 5.22 | EPS next 5Y | - | 52W High Chg | -10.00% |
| Recommedations | 4.00 | Quick Ratio | 0.86 | Shares Outstanding | 526.41M | 52W Low Chg | 57.00% |
| Insider Own | - | ROA | 6.65% | Shares Float | 133.89M | Beta | 0.31 |
| Inst Own | 0.01% | ROE | 12.19% | Shares Shorted/Prior | -/- | Price | 18.46 |
| Gross Margin | 54.20% | Profit Margin | 17.01% | Avg. Volume | 15,525 | Target Price | - |
| Oper. Margin | 28.04% | Earnings Date | - | Volume | 43,524 | Change | -2.28% |
Chr. Hansen Holding A/S, a bioscience company, develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific. The company operates through Food Cultures & Enzymes, and Health & Nutrition segments. The Food Cultures & Enzymes segment produces and sells various cultures, enzymes, and probiotic products that determine the taste, flavor, texture, shelf life, nutritional value, and health benefits of various consumer products in the food industry, primarily in the dairy industry. The Health & Nutrition segment produces and sells products for the dietary supplement, over-the-counter pharmaceutical, infant formula, animal feed, and plant protection industries. It has a strategic collaboration with UPL Ltd. to develop and commercialize microbial-based bio solutions for sustainable agriculture. The company was founded in 1843 and is headquartered in Hørsholm, Denmark. As of January 29, 2024, Chr. Hansen Holding A/S operates as a subsidiary of Novozymes A/S.